Moreover, exenatide administration in one Wolfram syndrome 2 patient resulted in a 70% reduction in daily insulin requirements, improved glycemic control, and 7-fold increase in maximal insulin secretion (Danielpur et al., 2016). This evidence concerns the gene INS and Wolfram syndrome 2.